Check4Cancer at MedTech Malta
Digital Innovation for Early Cancer Detection
Advancing cancer detection with AI, home imaging and personalised risk assessment.
Meet us at MedTech Malta
We’re proud to showcase our innovations at MedTech World Malta, 12–14 November 2025.
Visit us at Stand S001.
Join Professor Gordon Wishart, Founder & Chief Medical Officer, as he presents on the future of AI and digital innovation in cancer detection.
Why visit us at MedTech Malta?
From Cancer Experts. For a Digital Future.
At Check4Cancer, we combine medical expertise with digital innovation to make earlier cancer detection more accessible, accurate, and cost-effective.
Discover our latest digital cancer services:
AI for Skin Cancer Detection
Built on a foundation of extensive clinical data.
- AI model developed in collaboration with the University of Essex
- Validated on tens of thousands of clinical images
- Designed to support faster, more accurate detection of melanoma and non-melanoma skin cancers
DigitalSkin Imaging App
Secure, high-quality skin monitoring - in your pocket.
- Capture clinical-grade skin images at home using a smartphone
- Enables early triage and remote dermatology consultation
- Empowers patients while reducing unnecessary clinic visits
MyCancerRisk© Questionnaire
Digital risk stratification for early intervention.
- Identifies higher-risk individuals for six common cancers (breast, cervical, colorectal, lung, prostate, skin)
- Simple online questionnaire with evidence-based algorithms
- Supports insurers, employers and healthcare providers to target prevention and screening
Professor Gordon Wishart
Chief Medical Officer
Professor Gordon Wishart is the founder, Chief Medical Officer and CEO of Check4Cancer, a leading early cancer detection and cancer prevention company. In 2016 Check4Cancer launched rapid access, streamlined and audited diagnostic pathways for breast and skin cancer to the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. In late 2017, Check4Cancer launched the first worldwide breast cancer risk test (MyBreastRisk) to combine genetic, family history and lifestyle risk factors to underpin a risk-stratified breast screening programme. As the former Director of the Cambridge Breast Unit from 2005-2010, and current Professor of Cancer Surgery at Anglia Ruskin School of Medicine since 2008, he has a strong track record in clinical research and modernisation of cancer diagnosis and treatment, with more than 100 peer-reviewed papers in scientific journals. In 2010 he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, now used worldwide.
Find out more
Why Check4Cancer?
66,000+ corporate cancer checks delivered.
Services designed and governed by leading UK cancer specialists.
Rated Excellent by employers and employees.
Wrap-around support: Education webinars, internal comms campaigns and marketing resources.
Let’s Collaborate
Interested in partnerships, research collaborations, or bringing digital cancer services to your market?